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Abstract: Candida is one of the most frequent pathogens isolated in bloodstream infections, and is 
associated with significant morbidity and mortality. In addition to haematological patients, there 
are several other populations with a substantial risk of developing invasiv
include patients undergoing prolonged hospitalisation with the use of broad
those fitted with intravascular catheters, admitted to both adult and neonate intensive care units 
(ICU)  or  gastrointestinal  surgery
chemotherapy. As a general rule, every immunocompromised patient might be at risk of 
infection, including, for example, diabetic patients.
The epidemiology of species responsible for IC ha
level,  shifting  from  C.  albicans
fluconazole (C. krusei and, to some extent, 
production (C. parapsilosis) or than might acquire resistance to azole during therapy.
Delaying the specific therapy has been shown to increase morbidity and mortality, but traditional 
microbiological diagnosis is poorly sensitive and slow. Thus, culture
therapy started too late. In order to reduce the mortality in IC, several management strategies have 
been developed: prophylaxis, empirical and pre
latter approaches allow to reduce the use of an
of IC. Non-invasive serological markers and scores based on clinical prediction rules such as the 
presence of risk factors or Candida 
prompt initiation of treatment. Although the use of these diagnostic tools in pre
is promising, the performance and cost
Agents  recommended  for  initial  treatment  of  candidemia  in  severely  ill  pati
echinocandins and lipid formulations of amphotericin B, while stable patients without risk factors 
for azole-resistance might be treated with fluconazole. 
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is one of the most frequent pathogens isolated in bloodstream infections, and is 
associated with significant morbidity and mortality. In addition to haematological patients, there 
are several other populations with a substantial risk of developing invasive candidiasis (IC). These 
include patients undergoing prolonged hospitalisation with the use of broad
those fitted with intravascular catheters, admitted to both adult and neonate intensive care units 
(ICU)  or  gastrointestinal  surgery wards  and  subjects  with  solid  tumours  undergoing  cytotoxic 
chemotherapy. As a general rule, every immunocompromised patient might be at risk of 
infection, including, for example, diabetic patients.
The epidemiology of species responsible for IC has been changing, both at local and worldwide 
to  non-albicans  species,  that  can  be  intrinsically  resistant  to 
and, to some extent, C. glabrata), difficult to eradicate because of biofilm 
) or than might acquire resistance to azole during therapy.
Delaying the specific therapy has been shown to increase morbidity and mortality, but traditional 
microbiological diagnosis is poorly sensitive and slow. Thus, culture-based treatment
therapy started too late. In order to reduce the mortality in IC, several management strategies have 
been developed: prophylaxis, empirical and pre-emptive therapy. Compared to prophylaxis, the 
latter approaches allow to reduce the use of antifungals by targeting only patients at very high risk 
invasive serological markers and scores based on clinical prediction rules such as the 
Candida colonisation, have been developed with the aim of allowing 
nitiation of treatment. Although the use of these diagnostic tools in pre
is promising, the performance and cost-effectiveness should be tested in large trials. 
Agents  recommended  for  initial  treatment  of  candidemia  in  severely  ill  pati
echinocandins and lipid formulations of amphotericin B, while stable patients without risk factors 
resistance might be treated with fluconazole. 
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Introduction: Candida is a yeast responsible for the 
majority of fungal infections in humans. This fungus 
causes pathologies of different severity, ranging from 
mucocutaneous infections to invasive disease that can 
involve  any  organ.  The  incidence  of  invasive 
candidiasis (IC), particularly candidemia, has increased 
significantly in recent years and Candida spp. is now 
the  fourth  most  common  pathogen  isolated  in  blood 
cultures in the US.
1 In Europe it ranks among the ten 
most frequently isolated pathogens.
2,3 Candidemia is a 
life-threatening  infection  with  high  morbidity  and 
mortality.
4-7 Even  in  the  most  recent  studies,  crude 
mortality  rates  reached  50-60%  in  critically  ill 
patients,
8-10 although  attributable  mortality  can  be 
substantially lower.
Immunocompromised  patients,  such  as  those 
affected  by  solid  tumours  or  haematological 
malignancies are at high risk for developing Candida
infection. However, the widespread use of fluconazole 
prophylaxis in haematological and stem cell transplant 
settings might be responsible for a decreased incidence 
of invasive Candida infections in these populations.
11
On  the  contrary,  patients  with  multiple  severe 
comorbidities,  undergoing  gastrointestinal  surgery  or 
admitted to ICU constitute now the largest population 
at  risk  for  developing  candidemia.
12 In  fact,  IC  can 
affect up to about 10% of all critically ill subjects.
13,14
Fungal infections are being increasingly diagnosed in 
these  patients,  because  advances  in  medical  science 
now allow patients in desperate underlying conditions 
to  survive.  However,  this  is  not  obtained  without  a 
price,  such  as  the  development  of  infectious 
complications.  Therefore,  the  population  of  subjects 
vulnerable to  a range of infections is  increasing  and 
this trend will likely continue. 
From  a  clinical  point  of  view,  Candida causes 
bloodstream  infections,  sometimes  with 
endophtalmitis,  followed  by  peritonitis  and  other 
abdominal  infection  and  endocarditis.  A  matter  of 
debate can be how often a blood culture positive for 
Candida represents the external sign of a deep-seated 
infection,  or  it  is  simply  a  bloodstream  infection 
without localisation. Most of the patients included in 
studies  on  epidemiology  or  treatment  of  invasive 
candidiasis  had  candidemia  (approximately  68-90%), 
with or without localisation, while peritonitis was the 
second most common disease (approximately 7-30% of 
subjects).
9,15,16 In  a  recent  French  study,  isolated 
candidemia,  IC  with  candidemia  and IC  without 
candidemia accounted each for 1/3 of all episodes of 
IC.
9 Additionally,  Candida  accounted  for 
approximately  3%  of  all  surgery-related  peritoneal 
infections, both community-acquired and nosocomial.
9
On the of main points regarding invasive Candida
infection is the fact that delaying antifungal treatment 
significantly increases mortality.
17-20 Even 12-24 hours 
delay can result in twofold increase in crude mortality 
rate  in  candidemia.
21,22 However,  nosocomial  fungal 
infections have one of the highest rates of inappropriate 
therapy, that consists mostly of omission of including 
an antifungal in the initial empirical therapy and use 
the  of  inadequate  doses,  all  of  which  have  been 
associated with increased mortality.
12,21-23 Additionally, 
the estimated cost of each episode of IC in hospitalised 
adults is tremendous.
24,25 Thus, high awareness of this 
infection,  early  diagnosis  and  appropriate  prompt 
therapy remain the cornerstone of treatment. 
During the last decade several new antifungal drugs
have  been  developed  and  obtained  approval  for 
treatment of Candida infections. Therefore, treating a 
candidemia has become a difficult exercise, because of 
the  need  to  make  the  appropriate  choice  at  the 
appropriate time. In the following lines we will try to 
discuss  epidemiology,  risk  factors,  diagnosis  and 
management of IC in non-haematological patients.
Epidemiology  of  invasive  candidiasis:  The 
epidemiology  of  Candida infections,  both  on  a 
worldwide  scale,  and  more  importantly  on  the  local 
level, has significant implications for the management 
of these infections. 
During the past two decades, most hospitals have 
reported a progressive shift in the species of Candida. 
In  the  past,  almost  all  the  isolates  responsible  for 
bloodstream infections  were  C.  albicans,  whereas  in 
recent  years  a  growing  proportion  of  episodes  of 
candidemia have been caused by Candida species other 
than  albicans.
26-31 Although,  C.  albicans remains  the 
predominant strain in most countries,
9,32,33 non-albicans 
species  are  increasingly common  and  in  some  adult 
ICUs  they  were  responsible  for  over  50%  of 
candidemias.
29,34 The  most  common  non-albicans 
species are C. parapsilosis and C. glabrata, followed 
by  C.  tropicalis and  C.  krusei.
9,29,35-37 Rare  species 
reported to cause candidemia include C. lusitaniae, C. 
guilliermondii, and C. rugosa.
12,35
Numerous studies have tried to find reasons for this 
shift and several risk factors have been associated with 
the emergence of non-albicans species.
30,38,39 It is likely 
that the widespread use of fluconazole can predispose 
patients to the development of infections due to species 
that  are  intrinsically  resistant  to  azoles  or  have 
developed  resistance  during  treatment.  Indeed,  the 
previous use of fluconazole has been found to be a risk 
factor  for  the  presence  of  non-albicans fungemia  in 
many studies,
29,30,40 even though others did not find the 
same  association.
28 In  particular,  risk  factors  for 
candidemia due to C. parapsilosis include the presence 
of in-dwelling devices, hyperalimentation and neonatal 
age.
35 The  specific  risk  factors  associated  with  ICMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1: Risk factors associated with invasive candidiasis in general and candidemia due to different Candida species.
1
1
Adapted from the following references: 
6,31,35 
2
Epidemics due to nosocomial horizontal transmission via hands of health personnel have been reported.
45,46
and  with  different  Candida species  are  outlined  in 
table 1.
The  overall  rise  in  the  incidence  of  non-albicans
strains  is  alarming,  since  there  are  important 
differences  among  species.  Specifically,  the  main 
difference  between  C.  albicans and  C.  krusei or  C. 
glabrata is the resistance to the most frequently used 
antifungal,  i.e.  fluconazole.
41 Therefore,  species 
identification and the knowledge of local epidemiology 
of  Candida strains  causing  candidemia  is  of  utmost 
importance for guiding appropriate empirical therapy. 
In  vitro  susceptibility  testing  of  clinical  isolates  of 
Candida might prove valuable for guiding therapy in 
patients who have received prior antifungal treatment 
or  who  are  not  responding  to  first  line  therapy, 
especially if performed by experience microbiologists.
Risk factors for invasive candidiasis and predictive
scores: The predominant source of invasive Candida
infections is endogenous, from superficial mucosal and 
cutaneous  colonisation  to  haematogenous 
dissemination,
42 although  cases  of  exogenous 
transmission  due  to  contaminated  materials  or 
transmission from healthcare workers to patients and 
from patients to patients have been described.
43-46 The 
suppression  of  the  normal  bacterial  flora  of  the 
gastrointestinal  tract  by  broad  spectrum  antibiotic 
therapy allows the yeast to proliferate and long-term 
and  high  density  colonisation  has  been  shown  to 
predispose  to  candidemia.
47,48 Numerous  other 
conditions,  frequent  in  hospitalised  patients,  such  as 
steroid  treatment  and  poor  control  of  blood  glucose 
concentrations  (diabetes)  have  been  described.  In 
addition, parenteral nutrition, intravascular catheters or 
ischemia and reperfusion, may damage the integrity of 
the  skin or gastrointestinal mucosa, with  traslocation 
and bloodstream invasion. In particular, as much as one 
third  of  patients  with  recurrent  gastrointestinal 
perforations,  anastomotic  leaks  or  necrotising 
pancreatitis develop IC (table 1).
49,50
The effort to identify patients who are at high risk 
of  developing  IC  has  been  made  in  order  to  reduce 
mortality  by  offering  them  prophylaxis,  empirical or 
pre-emptive  treatment.  Once  risk  factors  have  been 
reported,  they  were  combined  to  create  reliable  risk 
prediction scores. 
Candida colonisation index (CI), reported in 1994, 
was studied in a surgical population with the aim of 
predicting patients who would develop IC,
48 and was 
used as a base for pre-emptive therapy.
51Although it is 
highly  predictive  for  IC,  its  routine  use  has  been 
limited by workload required and consequent costs. 
In  2006,  Leon  and  colleagues  described  their 
Candida Score (CS) system, that was helpful to select 
Candida species Risk factor
Candida in general
 Prior abdominal surgery
 Intravascular catheters
 Parenteral nutrition
 Use of broad-spectrum antibiotics
 Immunosuppression, including corticosteroid therapy





C. tropicalis  Neutropenia and bone marrow transplantation
C. krusei
 Fluconazole use













C. lusitaniae and C. guilliermondii  Previous polyene use
C. rugosa  BurnsMediterr J Hematol Infect Dis 2011; 3: Open Journal System
patients  who  could  benefit  from  early  antifungal 
therapy (those with CS > 2.5 were almost 8 times more 
likely  to  develop  IC  than  those  with  CS  <  2.5).
52
Subsequently, the same group validated their CS in a 
prospective  multicenter  trial  that  included  1107 
patients admitted for at least 7 days to ICU.
53 CS was 
calculated  as  follows:  1  point  for  the  presence  of 
parenteral  nutrition,  surgery  or  multifocal  Candida
colonization, 2 points for severe sepsis. In patients with 
Candida Score <3, the incidence of IC was 2.3%, thus 
allowing  to  withhold  empirical  antifungal  treatment. 
On the contrary, one of four patients with a CS of 5 
developed IC.
53
Another  clinical  risk  prediction  score  was 
developed  by  Ostrosky-Zeichner  and  colleagues.  In 
this  study, systemic  antibiotic  treatment  or  central 
venous  catheter,  combined  with  two  or  more  of 
additional  five  parameters  (parenteral  nutrition, 
dialysis,  major  surgery,  pancreatitis,  treatment  with 
steroids or other immunosuppressive agents), were able 
to identify patients with candidemia, with positive and 
negative  predictive  values  of  10%  and  97%, 
respectively.
54
Finally, Dupont and colleagues studied a predictive 
score  for  peritoneal  Candida infection  in  an  ICU 
population and found that the presence of 3 out of 4 
factors  (female  gender,  upper  gastrointestinal  tract 
origin  of  peritonitis,  intraoperative  cardiovascular 
failure  and  previous  antibiotic  therapy)  had  positive 
and  negative  predictive  values  of  67%  and  72%, 
respectively.
55
Diagnosis of candidemia: Blood cultures remain the 
mainstay  for  the  diagnosis  of  candidemia,  although 
sensitivity is not optimal and the time from the blood 
sample collection to the microbiological response of a 
growing  yeast  is  long.  Furthermore,  at  least  24-48 
hours  are  required  for  species  identification  and 
susceptibility testing. Traditional cultures from sterile 
sites  other  than  the  bloodstream  (e.g.  peritoneum), 
remain useful for the diagnosis IC, but more sensitive 
and more rapid diagnostic methods are needed. 
In  recent  years,  non-invasive  markers  have  been 
investigated,  which  include  serological  markers 
(mannan,  antimannan  and  (1,3)-beta-D-glucan)  and 
polymerase chain reaction. Although the mannan and 
antimannan commercially available ELISA tests have 
been marketed for almost 10 years, the only data derive 
from a single-centre studies that differ significantly in 
terms of sensitivity and specificity.
56-59 The (1,3)-beta-
D-glucan  test  has  been  marketed  more  recently  in 
Europe  and  in  the  US.  Despite  promising  results  in 
various  cohorts,  no  large  prospective  study  able  to 
evaluate  sensitivity,  specificity,  and  especially  cost-
effectiveness,  has  been  performed.
60,61 The  main 
problems of the routine use of (1,3)-beta-D-glucan are 
its  high  cost  and  high  rate  of  false  positive  results. 
Indeed,  (1,3)-beta-D-glucan  is  ubiquitous  in  nature 
contamination can be caused by concomitant bacterial 
bloodstream  infections,  presence  of  surgical  gauzes, 
use  of  glucan-containing  membranes  for 
haemofiltration  and  use  of  albumin  or 
immunoglobulins.
62 For  example,  in  a  study  that 
focused on the validation of the Candida Score, (1,3)-
beta-D-glucan testing was performed in a subgroup of 
240  patients  with  Candida species  colonisation  or 
invasive fungal infection.
53 For a cut-off of 75 pg/ml, 
good  sensitivity  of  77.8%  was  reported,  but  the 
specificity  was  low  (52.7%).  In  particular,  among 
patients  with  a  positive  result,  only  12%  developed 
documented invasive candidiasis. However, a positive 
(1,3)-beta-D-glucan  result  is  one  of  microbiological 
criteria  defining a  probable  invasive fungal infection 
according  to  2008  definitions  of  invasive  fungal 
disease  published  by  the  European  Organization  for 
Research and Treatment of Cancer and the Infectious 
Diseases Mycoses Study Group (EORTC/MSG).
63
Finally,  two  new  rapid  methods  are  available  for 
species identification and they include matrix-assisted 
laser  desorption  ionization  time-of-flight  mass 
spectrometry (MALDI-TOF MS) and fluorescence in-
situ hybridization (FISH). 
Management of candidemia in non-haematological 
setting: Different management strategies cen be used 
for managing suspected or documented IC, including 
prophylaxis,  empirical  or  pre-emptive  therapy  and 
treatment of a culture-proven infection. Based on the 
incidence  of  IC,  prophylaxis  may  be  judged 
appropriate in patients with high risk of IC (incidence 
> 10%). In settings with lower incidence rate, patients 
might  benefit  from  pre-emptive  strategies  based  on 
predictive scores. Obviously,  the  knowledge  of local 
epidemiology  helps  to  define  the  most  appropriate 
antifungal therapy, based on the most frequent species 
and  susceptibility  patterns  of  Candida isolated  in  a 
single centre. 
Prophylaxis,  defined  as  administration  of  an 
antifungal to a patient with no evidence of infection, 
has been evaluated in surgical and critically ill patients 
in several studies and metaanalyses.
33,64-73 Fluconazole 
prophylaxis  reduced  by  approximately  50%  the 
incidence of IC, and seemed associated with improved 
outcome.
70-72 Naturally,  antifungal  prophylaxis  is 
efficacious and cost-effective in populations with high 
prevalence  of  IC,  when  the  number  of  patients  that 
need to receive the prophylactic treatment in order to 
prevent one episode of IC (number needed to treat) is 
low.  On  the  other  hand,  the  disadvantages  of 
fluconazole  prophylaxis  include  overtreatment, Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
possible  toxicity  and  profound  influence  on  local 
epidemiology  with  the  emergence  of  azole-resistant 
isolates.
74 Therefore, antifungal  prophylaxis might  be 
indicated only for patients or procedures in which the 
rate  of  IC  is  higher  than  10%,  as  compared  to  the 
normal  rates  of  1-2%.
41,54,75 In  such  populations,  the 
number needed to treat is less than 20, as compared 
with over 100 in an average population of ICU patients 
with the incidence of IC of 2%. 
Empirical treatment is defined as the administration 
of antifungals in the presence of persistent or refractory 
fever in subjects who are at high risk of developing a 
fungal  infection.  This  strategy  has  been  developed 
almost 3 decades ago for neutropenic cancer patients, 
when it became evident that the lack of sensitivity of 
microbiological  and  clinical  findings  was  likely 
resulting in delayed diagnosis and increased morbidity 
and mortality.
76 Although the first studies on empirical 
therapy  had  numerous  methodological  flaws,  this 
fever-driven strategy is being used in different clinical 
settings and various antifungals are recommended for 
empirical  treatment  of  invasive  candidiasis,  both  in 
neutropenic and non-neutropenic patients.
41 However, 
in ICU or surgery patients, there are several causes of 
protracted  fever  and,  probably  for  this  reason,  in  a 
randomised multicenter study in critically ill patients, 
the empirical therapy with fluconazole was not more 
beneficial than placebo.
77
With  the  availability  of  diagnostic  tools  such  as 
radiological  imaging,  invasive  diagnostic  procedures, 
improved cultures techniques and serological markers, 
it became evident that a diagnosis-driven approach was 
possible and should be pursued. Pre-emptive treatment 
is  characterised  by  starting  antifungal  therapy  when 
one or more microbiological or clinical markers result 
positive.  Microbiological  markers  include  multiple 
colonisation, positivity of mannan, (1,3)-beta-D-glucan 
or  molecular  testing.
60,62 However,  there  is  a  certain 
degree  of  confusion  between  prophylaxis,  empirical 
and pre-emptive treatment in patients with high risk of 
IC, as defined by high Candida colonisation index. In 
fact,  the  IDSA  guidelines  recommend  a  pre-emptive 
approach (although they continue to call it empirical 
treatment) based on clinical assessment of risk factors, 
serologic markers, and/or culture data from nonsterile 
sites, rather than fever.
41
Despite all the advances in diagnostic tools, it is to 
be remembered that repeated blood cultures, both from 
CVC  and  peripheral  line,  remain  the  cornerstone  of 
diagnosis of candidemia, and that any positive blood 
culture for Candida must be taken seriously and needs 
appropriate treatment. 
Broad  spectrum  antifungals  are  recommended  for 
the first line treatment while species identification is 
pending, but when species is  known, a de-escalation 
can  be  recommended.
41 The  initial  choice  of 
antifungals depends on patient’s clinical condition and 
the risk of azole-resistant strain, due to previous azole 
exposure  or  local  epidemiology.
41 For  patients  in 
severe  or  moderately  severe  clinical  conditions  (e.g. 
hemodynamically  unstable,  or  with  suspected 
concomitant organ involvement), echinocandins are the 
first  choice  because  of  their  cidal  activity  against 
Candida and  excellent  toxicity  profile.
41 Liposomal 
amphotericin B - another fungicidal agent indicated for 
first  line  treatment  in  critically  ill  patients,  is  more 
expensive  and  probably  associated  with  a  higher 
toxicity. 
Other aspects of treating invasive candidiasis: Once 
the  initial  therapy  for  candidemia is  started,  several 
clinical issues remain open. First, the efficacy of the 
treatment should be assessed by the documentation of 
blood cultures returning sterile. Indeed, the date of the 
first negative blood culture is important, because the 
recommended length of treatment is 14 days after the 
last positive blood culture and resolution of symptoms 
attributable to candidemia.
Second,  the  antifungal  chosen  initially  can  be 
changed  on  the  basis  of  species  identification  or 
susceptibility testing. Thus, for stable patients with C. 
albicans or other azole-susceptible strains, fluconazole 
probably  remains  the  drug  of  choice.  Fluconazole 
might be preferred over echinocandins for treating C 
parapsilosis, as caspofungin MICs for C. parapsilosis 
are  higher  than  those for  other  Candida  species.
41,78
However, in a recent analysis of data from five clinical 
trials,  that  included  71  cases  of  infection  due  to  C. 
parapsilosis,  the  success  rate  was  comparable  with 
other non-albicans species.
79
Third,  patients  who  improve  clinically  and  who 
cleared  Candida from  the  bloodstream,  might  be 
suitable  for  step-down  oral  therapy  to  complete  the 
course of 14 days. The available oral antifungals are 
fluconazole,  itraconazole,  voriconazole  and 
posaconazole.  Fluconazole  is  an  obvious  choice  for 
susceptible  species,  while  voriconazole  can  be 
indicated  as  step-down  therapy  for  C.  krusei or 
voriconazole-susceptible C. glabrata and in ocular or 
cerebral  infections,  because  of  excellent  tissue 
concentration.
Additionally, ophthalmologic fundus examination is 
indicated in all patients to exclude endocular infection, 
while  endocarditis  should  be  excluded  in  case  of 
persistently  positive  blood  cultures,  known  valve 
pathology or any other sign or symptom suggestive of 
endocardial  involvement.  As  described  elsewhere,  in 
both these complicated cases the duration of treatment 
should be much longer (more than 4 weeks and up to
lifelong suppressive therapy).
41Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Finally,  intravenous  catheter  removal  is  strongly 
recommended for patients with candidemia. Indeed all 
guidelines, both on the management of candidiasis and 
on  the  management  of  catheter-related  bloodstream 
infections,  state  clearly  that  catheters  should  be 
removed,  even  though  one  should  admit  that  all 
statements indicate grade II or III of scientific validity 
of recommendation, in absence of data from properly 
randomised, controlled trials.
41,80,81 However, the issue 
might still be controvertial since a recent study, based 
on  a  multivariate  analysis  of 842  adults  included  in 
candidemia trials,  did  not  find  any  benefit  of  early 
central venous catheter removal (i.e. within 24 or 48 
hours  after  initiation  of  antifungal  therapy)  on 
survival.
81
Conclusions:  Candida is  one  of  the  most  common 
causes  of  nosocomial bloodstream  infection.  Non-
neutropenic  patients  now  constitute  a  large  but 
heterogeneous  population  of  patients  at  risk  of  IC, 
which includes subjects admitted to adult or neonatal 
ICU,  undergoing  abdominal  surgery  and  those  with 
cancer  or  numerous  medical  comorbidities  8e.g. 
diabetes).  Morbidity  and  mortality  associated  with 
candidemia  are  significant  and  the  epidemiology  of 
species  have  been  shifting  towards  non-albicans 
strains. Even though numerous risk factors for invasive 
Candida infection  have  been  reported  and  several 
antifungals  are  widely  available,  the  optimal 
management  of  candidemia  remains  a  challenge. 
Prophylaxis  might  be  beneficial  in  population  with 
incidence  >  10%,  while  novel  diagnostic  techniques 
should  be  further  studied  to  enable  pre-emptive 
treatment  in  populations  with  lower  incidence  rates. 
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